Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuneering Corp.

This article was originally published in Start Up

Executive Summary

Immuneering Corp. is developing mathematical models to predict whether a drug is likely to activate a patient's immune system to aid in fighting cancer and autoimmune diseases. The company's modeling application works with data from patient blood and tumor samples. Immuneering plans to offer its services to drug makers as a way of sorting patients into subpopulations, to understand the workarounds cancers develop against therapies, and to predict efficacy.
Advertisement

Related Content

Rhenovia Pharma SAS
Champions Biotechnology Inc.
Cytox Ltd.
Looking Forward to Pharma's Decade of Predictive Efficacy
Start-Up Previews (09/2009)
Looking Forward to Pharma's Decade of Predictive Efficacy
Start-Up Previews (09/2009)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel